| Literature DB >> 28949774 |
James R Hocker1, Subrato J Deb2, Min Li2, Megan R Lerner2,3, Stan A Lightfoot3, Aurelien A Quillet1, R Jane Hanas1, Matthew Reinersman2, Jess L Thompson2, Nicole T Vu4, Thomas C Kupiec4, Daniel J Brackett3, Marvin D Peyton2, Stephen M Dubinett5, Harold M Burkhart2, Russell G Postier2, Jay S Hanas1,2,3.
Abstract
A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.Entities:
Keywords:
Mesh：
Substances：
Year: 2017 PMID： 28949774 DOI： 10.1080/07357907.2017.1373120
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176